142 filings
Page 5 of 8
8-K
2swllu
1 Aug 18
Mirati Therapeutics Reports Second Quarter
4:25pm
8-K
b1eii2d 0md
7 Jun 18
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
4:03pm
8-K
96rjtw
18 May 18
Submission of Matters to a Vote of Security Holders
4:26pm
8-K
ez1yqo0xf47vi0a
7 May 18
Mirati Therapeutics Reports First Quarter
4:31pm
8-K
wvoamj 6ceq
24 Apr 18
Mirati Therapeutics Announces Progress of Lead Programs
12:00am
8-K
1fe2 v3wg14mf1dj
10 Apr 18
Entry into a Material Definitive Agreement
12:00am
8-K
0emmkeszv589myp
8 Mar 18
Mirati Therapeutics Reports Fourth Quarter and Full-year 2017 Financial Results
12:00am
8-K
snxqx1tr0arqnbc 9aot
24 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
mbz85phl45ibi6y
11 Jan 18
BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region
12:00am
8-K
4y8vngymej9ay1jyst
16 Nov 17
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
12:00am
8-K
62urnq7b
13 Nov 17
Mirati Therapeutics Announces Advancement of First-in-class Opportunities with Sitravatinib and Kras Inhibitor Programs
12:00am
8-K
4bc06hrimshjc6
1 Nov 17
Mirati Therapeutics Reports Third Quarter 2017
12:00am
8-K
n84 vfqbi71zbgyp
14 Sep 17
Mirati Therapeutics Presents Positive Preliminary
12:00am
8-K
6t985fnl
3 Aug 17
Mirati Therapeutics Reports Second Quarter 2017
12:00am
8-K
aylflvc4pr2ywzswgw
27 Jun 17
Mirati Therapeutics Announces Appointment of
12:00am
8-K
gylmcs97jzgf4lxl
19 May 17
Departure of Directors or Certain Officers
12:00am
8-K
765s1
4 May 17
Mirati Therapeutics Reports First Quarter 2017
12:00am
8-K
mzfrejcfo32mowx
27 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
5lasv1rtx
9 Mar 17
Mirati Therapeutics Reports Financial Results and Provides Business
12:00am
8-K
r5cgoqp sk1xsh1p
1 Feb 17
Departure of Directors or Certain Officers
12:00am